Results 141 to 150 of about 98,565 (232)
The graphical abstract provides a view on selected aspects of the pathogenesis, risk stratification and treatment of acute GVHD. Summary Acute graft‐versus‐host disease (aGVHD) remains a major complication following allogeneic haematopoietic stem cell transplantation (allo‐HSCT), representing a leading cause of non‐relapse mortality (NRM) and ...
Hazim Khatib, Robert Zeiser
wiley +1 more source
The immunological landscape of the area postrema in neuromyelitis optica spectrum disorders
Aquaporin‐4 antibody‐positive neuromyelitis spectrum disorder is characterized by large tissue destructive lesions in medulla, spinal cord, and optic nerves, with only partial recovery from clinical symptoms, and by lesions with very little tissue destruction and mostly complete recovery from clinical symptoms, as seen in the area postrema ...
Qian Yu +11 more
wiley +1 more source
Targeting of C‐type lectin‐like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides: reply [PDF]
C, Delierneux +5 more
openaire +2 more sources
Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu +6 more
wiley +1 more source
Targeting KRAS for cancer therapy
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia +4 more
wiley +1 more source
CD93—An emerging vascular target in cancer therapy
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira +3 more
wiley +1 more source
The fight of innate immunity and abnormal cannabinoids against Candida infection
Candida species represent the most clinically significant fungal pathogens in humans, with invasive candidiasis carrying a mortality of 30%–40% in critically ill patients despite modern antifungal therapy. The innate immune system – through the coordinated and specific activities of neutrophils, macrophages, NK cells, mast cells and eosinophils ...
Prince Ofori +2 more
wiley +1 more source
Intravenous (IV) or intratumoral (IT) cetuximab distribution in A431 tumor (essence of Figure 2). ABSTRACT Near‐infrared photoimmunotherapy (NIR‐PIT) is a new type of cancer treatment that specifically kills target cells while sparing normal tissue. This treatment induces cancer cell death by activating a photoreactive dye with near‐infrared light in ...
Miyu Kano +9 more
wiley +1 more source
Conserved dimerization architecture in C‐type lectins from virus‐vector mosquitoes
C‐type lectins (CTLs) are involved in the detection of viral/microbial carbohydrates. We studied a family of soluble CTLs in the mosquito Aedes aegypti, which acts as a vector for viruses like dengue and Zika. Using crystallography, biophysics, and structure prediction approaches, we found that these proteins consistently pair together in the same ...
Mattia Bertinelli +6 more
wiley +1 more source
FTO regulates mRNA stability and translational efficiency through its m6A‐demethylation activity. GSK3 functions as an upstream regulator of FTO, leading to its inhibition via phosphorylation. In male germ cells, FTO activity is kept in check by GSK3α.
Neha Choudhari +7 more
wiley +1 more source

